RituximabRecent, repeatedEvidence- NCT07753369 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Rituximab injection” · registered Aug 2026
- NCT07520006 · Nurix Therapeutics, Inc. · Phase 2 · live · background · “rituximab” · registered Apr 2026
- NCT07139873 · Dizal Pharmaceuticals · Phase 3 · live · comparator · “Rituximab” · registered Aug 2025
- NCT06970743 · BeOne Medicines · Phase 3 · live · background · “Rituximab” · registered May 2025
- NCT06846671 · BeOne Medicines · Phase 3 · live · comparator · “Rituximab” · registered Feb 2025
| Hoffmann-La Roche45% of its industry studiesUS: Hoffmann-La Roche (FDA 1997) + 3 othersEU: Hoffmann-La Roche (EMA 1998) + 6 others | 79 studies | 1017 studies | comparator 12 · background 21 |
bendamustineRecent, repeatedEvidence- NCT07753369 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Bendamustine Injection” · registered Aug 2026
- NCT07139873 · Dizal Pharmaceuticals · Phase 3 · live · comparator · “Bendamustine” · registered Aug 2025
- NCT06970743 · BeOne Medicines · Phase 3 · live · background · “Bendamustine” · registered May 2025
- NCT06846671 · BeOne Medicines · Phase 3 · live · comparator · “Bendamustine” · registered Feb 2025
- NCT06205290 · Bristol-Myers Squibb · Phase 3 · comparator · “Bendamustine” · registered Dec 2023
| Teva Pharmaceutical Industries, Ltd.25% of its industry studiesUS: off-patent, 3 generics marketed | 56 studies | 68 studies | comparator 11 · background 11 |
venetoclaxRecent, repeatedEvidence- NCT07520006 · Nurix Therapeutics, Inc. · Phase 2 · live · background · “venetoclax” · registered Apr 2026
- NCT07277231 · BeOne Medicines · Phase 3 · live · comparator · “Venetoclax” · registered Dec 2025
- NCT07154264 · Dizal Pharmaceuticals · Phase 2 · live · background · “Venetoclax” · registered Aug 2025
- NCT06943872 · BeOne Medicines · Phase 3 · live · comparator · “Venetoclax” · registered Apr 2025
- NCT06846671 · BeOne Medicines · Phase 3 · live · comparator · “Venetoclax” · registered Feb 2025
| AbbVie64% of its industry studiesUS: AbbVie (FDA 2016)EU: AbbVie (EMA 2016) | 47 studies | 610 studies | background 12 · comparator 4 |
CyclophosphamideRecent, repeatedEvidence- NCT06564038 · AstraZeneca · Phase 2 · live · background · “Cyclophosphamide” · registered Aug 2024
- NCT06205290 · Bristol-Myers Squibb · Phase 3 · background · “Cyclophosphamide” · registered Dec 2023
- NCT05624554 · Merck & Co., Inc · Phase 3 · live · comparator · “Cyclophosphamide” · registered Nov 2022
- NCT04623541 · Genmab · Phase 2 · live · background · “rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone” · registered Oct 2020
- NCT04416984 · Allogene Therapeutics · Phase 2 · live · background · “Cyclophosphamide” · registered May 2020
| Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed | 33 studies | 44 studies | background 10 · comparator 2 |
idelalisibRecent, repeatedEvidence- NCT07139873 · Dizal Pharmaceuticals · Phase 3 · live · comparator · “Idelalisib” · registered Aug 2025
- NCT06846671 · BeOne Medicines · Phase 3 · live · comparator · “Idelalisib” · registered Feb 2025
- NCT06205290 · Bristol-Myers Squibb · Phase 3 · comparator · “Idelalisib” · registered Dec 2023
- NCT04666038 · Eli Lilly and Company · Phase 3 · live · comparator · “Idelalisib” · registered Dec 2020
- NCT02970318 · AstraZeneca · Phase 3 · live · comparator · “Idelalisib” · registered Nov 2016
| Gilead Sciences93% of its industry studiesUS: Gilead Sciences (FDA 2014)EU: Gilead Sciences (EMA 2014) | 33 studies | 44 studies | comparator 5 · background 1 |
ibrutinibRecent, repeatedEvidence- NCT06136559 · Merck & Co., Inc · Phase 3 · live · comparator · “Ibrutinib” · registered Nov 2023
- NCT05254743 · Eli Lilly and Company · Phase 3 · live · comparator · “Ibrutinib” · registered Feb 2022
- NCT04494503 · Ascentage Pharma Group International · Phase 2 · live · background · “Ibrutinib” · registered Jul 2020
- NCT04016805 · TG Therapeutics, Inc. · Phase 2 · background · “Ibrutinib” · registered Jul 2019
- NCT03734016 · BeOne Medicines · Phase 3 · comparator · “Ibrutinib” · registered Nov 2018
| Johnson & Johnson46% of its industry studiesUS: AbbVie (FDA 2013)EU: Johnson & Johnson (EMA 2014) | 22 studies | 44 studies | comparator 5 · background 6 |
obinutuzumabRecent, repeatedEvidence- NCT07520006 · Nurix Therapeutics, Inc. · Phase 2 · live · background · “obinutuzumab” · registered Apr 2026
- NCT06970743 · BeOne Medicines · Phase 3 · live · background · “Obinutuzumab” · registered May 2025
- NCT06073821 · BeOne Medicines · Phase 3 · live · comparator · “Obinutuzumab” · registered Oct 2023
- NCT03492125 · MingSight Pharmaceuticals, Inc · Phase 2 · background · “obinutuzumab” · registered Mar 2018
- NCT03462719 · Johnson & Johnson · Phase 3 · live · comparator · “Obinutuzumab” · registered Mar 2018
| Hoffmann-La Roche76% of its industry studiesUS: Hoffmann-La Roche (FDA 2013)EU: Hoffmann-La Roche (EMA 2014) | 23 studies | 34 studies | background 9 · comparator 3 |
fludarabineRecent, repeatedPhase 4 trial recordedEvidence- NCT06205290 · Bristol-Myers Squibb · Phase 3 · background · “Fludarabine” · registered Dec 2023
- NCT05624554 · Merck & Co., Inc · Phase 3 · live · comparator · “Fludarabine” · registered Nov 2022
- NCT04416984 · Allogene Therapeutics · Phase 2 · live · background · “Fludarabine” · registered May 2020
- NCT04285567 · Hoffmann-La Roche · Phase 3 · comparator · “Fludarabine” · registered Feb 2020
- NCT02013817 · Hoffmann-La Roche · Phase 2 · background · “fludarabine” · registered Dec 2013
| Beijing Biotech18% of its industry studies | 22 studies | 22 studies | comparator 3 · background 5 |
acalabrutinibRecent, repeatedEvidence- NCT07277231 · BeOne Medicines · Phase 3 · live · comparator · “Acalabrutinib” · registered Dec 2025
- NCT06136559 · Merck & Co., Inc · Phase 3 · live · comparator · “Acalabrutinib” · registered Nov 2023
- NCT04502394 · Ipsen · Phase 2 · background · “acalabrutinib” · registered Jul 2020
- NCT04016805 · TG Therapeutics, Inc. · Phase 2 · background · “Acalabrutinib Oral Capsule” · registered Jul 2019
- NCT03492125 · MingSight Pharmaceuticals, Inc · Phase 2 · background · “acalabrutinib” · registered Mar 2018
| AstraZeneca95% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2020) | 22 studies | 22 studies | comparator 2 · background 3 |
pirtobrutinibRecent, repeatedEvidence- NCT07342478 · Lupeng Pharmaceutical Ltd. · Phase 3 · live · comparator · “Pirtobrutinib” · registered Jan 2026
- NCT06973187 · BeOne Medicines · Phase 3 · live · comparator · “Pirtobrutinib” · registered May 2025
| Eli Lilly and Company93% of its industry studiesUS: Eli Lilly and Company (FDA 2023)EU: Eli Lilly and Company (EMA 2023) | 22 studies | 22 studies | comparator 2 |